Neuraminidase inhibitor treatment is associated with decreased mortality in COVID-19 patients: a retrospective analysis
Abstract Aims The aim of this study was to investigate the effects of Neuraminidase inhibitors (NI) on COVID-19 in a retrospective study. Methods and results The study included an overall COVID-19 patients (n = 3267) and a 1:1 propensity score-matched patients (n = 972). The levels of plasma N-acety...
Saved in:
| Published in | European heart journal. Cardiovascular pharmacotherapy Vol. 8; no. 4; pp. 392 - 401 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Oxford University Press
01.07.2022
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2055-6837 2055-6845 2055-6845 |
| DOI | 10.1093/ehjcvp/pvac018 |
Cover
| Abstract | Abstract
Aims
The aim of this study was to investigate the effects of Neuraminidase inhibitors (NI) on COVID-19 in a retrospective study.
Methods and results
The study included an overall COVID-19 patients (n = 3267) and a 1:1 propensity score-matched patients (n = 972). The levels of plasma N-acetylneuraminic acid and neuraminidase expression were further evaluated in a panel of hospitalized and 1-month post-infection recovered COVID-19 subjects. The mortality rate in the overall patients was 9.6% (313/3267) and 9.2% (89/972) in the propensity-score matched patients. The NI treatment lowered the mortality rate (5.7% vs. 10.3%) and the critically ill conversion rate (14.1% vs. 19.7%) compare to those in the non-NI group in the overall patients and evaluated in the propensity score-matched patients when applying the multivariate Cox model for adjusting imbalanced confounding factors. Furthermore, NI treatment was associated with attenuated cytokine storm levels and acute heart injury but not liver or kidney injuries. Further analysis in a small panel of patients found the levels of N-acetylneuraminic acid and neuraminidase (dominantly the NEU3 isoform) were elevated in the hospitalized COVID-19 subjects and recovered at the 1-month post-infection stage, suggesting increasing desialylation in COVID-19 patients.
Conclusion
These results suggest that NI treatment is associated with decreased mortality in COVID-19 subjects, especially for those subjects with acute heart injury. |
|---|---|
| AbstractList | Abstract
Aims
The aim of this study was to investigate the effects of Neuraminidase inhibitors (NI) on COVID-19 in a retrospective study.
Methods and results
The study included an overall COVID-19 patients (n = 3267) and a 1:1 propensity score-matched patients (n = 972). The levels of plasma N-acetylneuraminic acid and neuraminidase expression were further evaluated in a panel of hospitalized and 1-month post-infection recovered COVID-19 subjects. The mortality rate in the overall patients was 9.6% (313/3267) and 9.2% (89/972) in the propensity-score matched patients. The NI treatment lowered the mortality rate (5.7% vs. 10.3%) and the critically ill conversion rate (14.1% vs. 19.7%) compare to those in the non-NI group in the overall patients and evaluated in the propensity score-matched patients when applying the multivariate Cox model for adjusting imbalanced confounding factors. Furthermore, NI treatment was associated with attenuated cytokine storm levels and acute heart injury but not liver or kidney injuries. Further analysis in a small panel of patients found the levels of N-acetylneuraminic acid and neuraminidase (dominantly the NEU3 isoform) were elevated in the hospitalized COVID-19 subjects and recovered at the 1-month post-infection stage, suggesting increasing desialylation in COVID-19 patients.
Conclusion
These results suggest that NI treatment is associated with decreased mortality in COVID-19 subjects, especially for those subjects with acute heart injury. Aims The aim of this study was to investigate the effects of Neuraminidase inhibitors (NI) on COVID-19 in a retrospective study. Methods and results The study included an overall COVID-19 patients (n = 3267) and a 1:1 propensity score-matched patients (n = 972). The levels of plasma N-acetylneuraminic acid and neuraminidase expression were further evaluated in a panel of hospitalized and 1-month post-infection recovered COVID-19 subjects. The mortality rate in the overall patients was 9.6% (313/3267) and 9.2% (89/972) in the propensity-score matched patients. The NI treatment lowered the mortality rate (5.7% vs. 10.3%) and the critically ill conversion rate (14.1% vs. 19.7%) compare to those in the non-NI group in the overall patients and evaluated in the propensity score-matched patients when applying the multivariate Cox model for adjusting imbalanced confounding factors. Furthermore, NI treatment was associated with attenuated cytokine storm levels and acute heart injury but not liver or kidney injuries. Further analysis in a small panel of patients found the levels of N-acetylneuraminic acid and neuraminidase (dominantly the NEU3 isoform) were elevated in the hospitalized COVID-19 subjects and recovered at the 1-month post-infection stage, suggesting increasing desialylation in COVID-19 patients. Conclusion These results suggest that NI treatment is associated with decreased mortality in COVID-19 subjects, especially for those subjects with acute heart injury. Keywords COVID-19 * Neuraminidase inhibitor * N-acetylneuraminic acid The aim of this study was to investigate the effects of Neuraminidase inhibitors (NI) on COVID-19 in a retrospective study. The study included an overall COVID-19 patients (n = 3267) and a 1:1 propensity score-matched patients (n = 972). The levels of plasma N-acetylneuraminic acid and neuraminidase expression were further evaluated in a panel of hospitalized and 1-month post-infection recovered COVID-19 subjects. The mortality rate in the overall patients was 9.6% (313/3267) and 9.2% (89/972) in the propensity-score matched patients. The NI treatment lowered the mortality rate (5.7% vs. 10.3%) and the critically ill conversion rate (14.1% vs. 19.7%) compare to those in the non-NI group in the overall patients and evaluated in the propensity score-matched patients when applying the multivariate Cox model for adjusting imbalanced confounding factors. Furthermore, NI treatment was associated with attenuated cytokine storm levels and acute heart injury but not liver or kidney injuries. Further analysis in a small panel of patients found the levels of N-acetylneuraminic acid and neuraminidase (dominantly the NEU3 isoform) were elevated in the hospitalized COVID-19 subjects and recovered at the 1-month post-infection stage, suggesting increasing desialylation in COVID-19 patients. These results suggest that NI treatment is associated with decreased mortality in COVID-19 subjects, especially for those subjects with acute heart injury. The aim of this study was to investigate the effects of Neuraminidase inhibitors (NI) on COVID-19 in a retrospective study.AIMSThe aim of this study was to investigate the effects of Neuraminidase inhibitors (NI) on COVID-19 in a retrospective study.The study included an overall COVID-19 patients (n = 3267) and a 1:1 propensity score-matched patients (n = 972). The levels of plasma N-acetylneuraminic acid and neuraminidase expression were further evaluated in a panel of hospitalized and 1-month post-infection recovered COVID-19 subjects. The mortality rate in the overall patients was 9.6% (313/3267) and 9.2% (89/972) in the propensity-score matched patients. The NI treatment lowered the mortality rate (5.7% vs. 10.3%) and the critically ill conversion rate (14.1% vs. 19.7%) compare to those in the non-NI group in the overall patients and evaluated in the propensity score-matched patients when applying the multivariate Cox model for adjusting imbalanced confounding factors. Furthermore, NI treatment was associated with attenuated cytokine storm levels and acute heart injury but not liver or kidney injuries. Further analysis in a small panel of patients found the levels of N-acetylneuraminic acid and neuraminidase (dominantly the NEU3 isoform) were elevated in the hospitalized COVID-19 subjects and recovered at the 1-month post-infection stage, suggesting increasing desialylation in COVID-19 patients.METHODS AND RESULTSThe study included an overall COVID-19 patients (n = 3267) and a 1:1 propensity score-matched patients (n = 972). The levels of plasma N-acetylneuraminic acid and neuraminidase expression were further evaluated in a panel of hospitalized and 1-month post-infection recovered COVID-19 subjects. The mortality rate in the overall patients was 9.6% (313/3267) and 9.2% (89/972) in the propensity-score matched patients. The NI treatment lowered the mortality rate (5.7% vs. 10.3%) and the critically ill conversion rate (14.1% vs. 19.7%) compare to those in the non-NI group in the overall patients and evaluated in the propensity score-matched patients when applying the multivariate Cox model for adjusting imbalanced confounding factors. Furthermore, NI treatment was associated with attenuated cytokine storm levels and acute heart injury but not liver or kidney injuries. Further analysis in a small panel of patients found the levels of N-acetylneuraminic acid and neuraminidase (dominantly the NEU3 isoform) were elevated in the hospitalized COVID-19 subjects and recovered at the 1-month post-infection stage, suggesting increasing desialylation in COVID-19 patients.These results suggest that NI treatment is associated with decreased mortality in COVID-19 subjects, especially for those subjects with acute heart injury.CONCLUSIONThese results suggest that NI treatment is associated with decreased mortality in COVID-19 subjects, especially for those subjects with acute heart injury. The aim of this study was to investigate the effects of Neuraminidase inhibitors (NI) on COVID-19 in a retrospective study. The study included an overall COVID-19 patients (n = 3267) and a 1:1 propensity score-matched patients (n = 972). These results suggest that NI treatment is associated with decreased mortality in COVID-19 subjects, especially for those subjects with acute heart injury. Aims The aim of this study was to investigate the effects of Neuraminidase inhibitors (NI) on COVID-19 in a retrospective study. Methods and results The study included an overall COVID-19 patients (n = 3267) and a 1:1 propensity score-matched patients (n = 972). The levels of plasma N-acetylneuraminic acid and neuraminidase expression were further evaluated in a panel of hospitalized and 1-month post-infection recovered COVID-19 subjects. The mortality rate in the overall patients was 9.6% (313/3267) and 9.2% (89/972) in the propensity-score matched patients. The NI treatment lowered the mortality rate (5.7% vs. 10.3%) and the critically ill conversion rate (14.1% vs. 19.7%) compare to those in the non-NI group in the overall patients and evaluated in the propensity score-matched patients when applying the multivariate Cox model for adjusting imbalanced confounding factors. Furthermore, NI treatment was associated with attenuated cytokine storm levels and acute heart injury but not liver or kidney injuries. Further analysis in a small panel of patients found the levels of N-acetylneuraminic acid and neuraminidase (dominantly the NEU3 isoform) were elevated in the hospitalized COVID-19 subjects and recovered at the 1-month post-infection stage, suggesting increasing desialylation in COVID-19 patients. Conclusion These results suggest that NI treatment is associated with decreased mortality in COVID-19 subjects, especially for those subjects with acute heart injury. |
| Audience | Academic |
| Author | Wu, Junfang Wang, Dao Wen Li, Chenze Hu, Dong Zheng, Lemin Zhao, Mingming Wei, Haoran |
| Author_xml | – sequence: 1 givenname: Junfang surname: Wu fullname: Wu, Junfang – sequence: 2 givenname: Mingming surname: Zhao fullname: Zhao, Mingming – sequence: 3 givenname: Haoran surname: Wei fullname: Wei, Haoran – sequence: 4 givenname: Chenze surname: Li fullname: Li, Chenze – sequence: 5 givenname: Dong surname: Hu fullname: Hu, Dong – sequence: 6 givenname: Lemin surname: Zheng fullname: Zheng, Lemin – sequence: 7 givenname: Dao Wen surname: Wang fullname: Wang, Dao Wen email: dwwang@tjh.tjmu.edu.cn |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35294004$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUktv1DAQjlARLaVXjsgSFzik9SuJwwGpWl6VKnqpuFpeZ9KdVRIH29lq_z2OdtnSCoR88Njzfd88X2ZHgxsgy14zes5oLS5gtbab8WLcGEuZepadcFoUealkcXSwRXWcnYWwppSyUpVciRfZsSh4LSmVJ9n9d5i86XHAxgQgOKxwidF5Ej2Y2MMQCQZiQnAWTYSG3GNckQZscof07J2PpsO4TVSyuPlx9SlnNRlNxEQNH4ghHqJ3YQQbcQPEDKbbBgyvsuet6QKc7e_T7PbL59vFt_z65uvV4vI6twWrY57ybBnlqpFVyn1pS8ZNoWQtSkuLpZUWFHAuk0G5pJwJYK1sSymhbA2txGn2cSc7TsseGpuS8qbTo8fe-K12BvVjz4Arfec2WtU1F7RMAu_2At79nCBE3WOw0HVmADcFzcu5j1KoGfr2CXTtJp_qnVFVwRWravmAujMdaBxal-LaWVRfVoUSoqjLWev8L6h0GujRpi1oMf0_Irz5s9BDhb8n_aBo0zSCh_YAYVTP26R326T325QI8gnBYkxzdXOjsPs37f2O5qbxfyF-Acur36o |
| CitedBy_id | crossref_primary_10_1080_00032719_2023_2248530 crossref_primary_10_12677_ACM_2024_143662 crossref_primary_10_3390_cells12091332 crossref_primary_10_3390_ijms24010239 crossref_primary_10_1007_s10800_024_02213_w crossref_primary_10_7189_jogh_15_04056 |
| Cites_doi | 10.3201/eid2504.181595 10.1093/cvr/cvaa106 10.1186/s12879-018-3223-5 10.1016/j.cmet.2020.06.016 10.1038/s41422-020-0327-4 10.1016/S0022-2143(02)00025-2 10.1016/0042-6822(74)90276-1 10.1186/s12872-020-01690-z 10.1038/s41598-017-15198-8 10.1093/eurheartj/ehaa575 10.1161/CIRCULATIONAHA.117.031139 10.3201/eid1004.030458 10.1038/s41577-020-0311-8 10.1136/bmj.302.6769.143 10.1016/S0140-6736(20)30183-5 10.1056/NEJMoa2023184 10.1016/j.ajpath.2020.09.011 10.1001/jama.2020.10245 10.1159/000339789 10.1007/s00059-020-04909-z 10.1056/NEJMoa2002032 10.3390/cells9091963 10.1056/NEJMoa2021436 10.1111/jth.14817 10.1093/eurheartj/ehab347 10.1038/s41467-020-20457-w 10.1038/nrcardio.2015.108 10.1016/j.cmet.2020.11.014 10.1016/j.ejphar.2018.11.014 10.1038/s41392-020-00360-y |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. 2022 The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. COPYRIGHT 2022 Oxford University Press The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. 2022 – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. – notice: COPYRIGHT 2022 Oxford University Press – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | TOX AAYXX CITATION NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM |
| DOI | 10.1093/ehjcvp/pvac018 |
| DatabaseName | Oxford Journals Open Access Collection CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic ProQuest One Academic Middle East (New) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 3 dbid: 7X7 name: Health & Medical Collection (ProQuest) url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2055-6845 |
| EndPage | 401 |
| ExternalDocumentID | PMC8992306 A758335966 35294004 10_1093_ehjcvp_pvac018 10.1093/ehjcvp/pvac018 |
| Genre | Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: 91639108 – fundername: Sino-German Center grantid: C0052 – fundername: ; grantid: 91639108; 81790624; 81970425; 31971358 – fundername: ; grantid: C0052 |
| GroupedDBID | 0R~ 1TH 3V. 4.4 48X 53G 5WD 7X7 88E 8FI 8FJ AABZA AACZT AAJQQ AAOGV AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP ABNHQ ABPQP ABPTD ABQLI ABQNK ABUWG ABWST ABXVV ADBBV ADGZP ADHKW ADIPN ADQBN ADRTK ADVEK AETBJ AEWNT AFFZL AFKRA AFOFC AFXEN AGINJ AGQXC AGUTN AHMBA AJEEA ALIPV ALMA_UNASSIGNED_HOLDINGS ATGXG AVWKF BAYMD BCRHZ BENPR BEYMZ BHONS BPHCQ BTRTY BVXVI C45 CCPQU CDBKE DAKXR EBS EJD ENERS FECEO FLUFQ FOEOM FOTVD FQBLK FYUFA GAUVT GJXCC H13 HMCUK IAO KBUDW KOP KSI KSN M1P MHKGH NOMLY NOYVH O9- OAUYM OAWHX OCZFY ODMLO OJZSN OPAEJ OVD OWPYF PAFKI PEELM PQQKQ PROAC PSQYO ROX RUSNO RXO TEORI TJX TOX UKHRP YAYTL YKOAZ YXANX AAYXX ABEJV ABGNP ABVGC ADNBA ADPDF AEMQT AFXAL AHGBF AJNCP ALXQX AMNDL CITATION IHR ITC NU- PHGZM PHGZT RPM AHMMS NPM PMFND 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI PUEGO 7X8 5PM |
| ID | FETCH-LOGICAL-c519t-529f1028d47862bc612a584936c05bc4ce8e224c4c0240213e1f4f644e6fa073 |
| IEDL.DBID | 7X7 |
| ISSN | 2055-6837 2055-6845 |
| IngestDate | Thu Aug 21 14:22:38 EDT 2025 Fri Sep 05 10:25:57 EDT 2025 Fri Sep 19 20:56:41 EDT 2025 Tue Jun 17 21:37:59 EDT 2025 Tue Jun 10 21:27:30 EDT 2025 Thu Apr 03 07:03:32 EDT 2025 Tue Jul 01 01:13:57 EDT 2025 Thu Apr 24 23:10:37 EDT 2025 Wed Aug 28 03:18:15 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | COVID-19 Neuraminidase inhibitor acetylneuraminic acid N-acetylneuraminic acid |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com https://creativecommons.org/licenses/by-nc/4.0 The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c519t-529f1028d47862bc612a584936c05bc4ce8e224c4c0240213e1f4f644e6fa073 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally: Junfang Wu, Mingming Zhao. |
| OpenAccessLink | https://dx.doi.org/10.1093/ehjcvp/pvac018 |
| PMID | 35294004 |
| PQID | 2675281794 |
| PQPubID | 2046366 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8992306 proquest_miscellaneous_2640044386 proquest_journals_2675281794 gale_infotracmisc_A758335966 gale_infotracacademiconefile_A758335966 pubmed_primary_35294004 crossref_primary_10_1093_ehjcvp_pvac018 crossref_citationtrail_10_1093_ehjcvp_pvac018 oup_primary_10_1093_ehjcvp_pvac018 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-07-01 |
| PublicationDateYYYYMMDD | 2022-07-01 |
| PublicationDate_xml | – month: 07 year: 2022 text: 2022-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | European heart journal. Cardiovascular pharmacotherapy |
| PublicationTitleAlternate | Eur Heart J Cardiovasc Pharmacother |
| PublicationYear | 2022 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | Wielgat (2022060809381142300_bib17) 2020; 9 Collet (2022060809381142300_bib21) 2021; 42 Tan (2022060809381142300_bib28) 2004; 10 Chen (2022060809381142300_bib15) 2021; 42 Tay (2022060809381142300_bib2) 2020; 20 Khwaja (2022060809381142300_bib23) 2012; 120 Sanders (2022060809381142300_bib8) 2020; 323 Li (2022060809381142300_bib24) 2021; 14 Pilling (2022060809381142300_bib30) 2021; 191 Yu (2022060809381142300_bib7) 2020; 63 Al-Abdely (2022060809381142300_bib10) 2019; 25 Song (2022060809381142300_bib29) 2020; 32 Chen (2022060809381142300_bib34) 2020; 45 Marrone (2022060809381142300_bib22) 2017; 21 Huang (2022060809381142300_bib11) 2020; 395 Marovich (2022060809381142300_bib3) 2020; 324 Chu (2022060809381142300_bib16) 2021; 12 Glanz (2022060809381142300_bib26) 2019; 842 Tang (2022060809381142300_bib5) 2020; 18 Pan (2022060809381142300_bib6) 2021; 384 Lindberg (2022060809381142300_bib13) 1991; 302 Zhang (2022060809381142300_bib14) 2018; 137 Guzik (2022060809381142300_bib33) 2020; 116 Huang (2022060809381142300_bib20) 2020; 395 Guan (2022060809381142300_bib25) 2020; 382 Palese (2022060809381142300_bib27) 1974; 61 World Health Organization (2022060809381142300_bib18) 2020 Li (2022060809381142300_bib32) 2020; 20 Karhadkar (2022060809381142300_bib31) 2017; 7 Horby (2022060809381142300_bib4) 2021; 384 Pollack (2022060809381142300_bib36) 2015; 12 Gokmen (2022060809381142300_bib12) 2002; 140 Cao (2022060809381142300_bib1) 2020; 30 Yu (2022060809381142300_bib19) 2021; 33 Hang (2022060809381142300_bib35) 2020; 5 Bleibtreu (2022060809381142300_bib9) 2018; 18 |
| References_xml | – year: 2020 ident: 2022060809381142300_bib18 article-title: Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspectedInterim guidance 13 march 2020 publication-title: WHO – volume: 25 start-page: 753 year: 2019 ident: 2022060809381142300_bib10 article-title: Middle East respiratory syndrome coronavirus infection dynamics and antibody responses among clinically diverse patients, Saudi Arabia publication-title: Emerg Infect. Dis. doi: 10.3201/eid2504.181595 – volume: 116 start-page: 1666 year: 2020 ident: 2022060809381142300_bib33 article-title: COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options publication-title: Cardiovasc Res doi: 10.1093/cvr/cvaa106 – volume: 18 start-page: 331 year: 2018 ident: 2022060809381142300_bib9 article-title: Clinical management of respiratory syndrome in patients hospitalized for suspected middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016 publication-title: BMC Infect Dis doi: 10.1186/s12879-018-3223-5 – volume: 32 start-page: 188 year: 2020 ident: 2022060809381142300_bib29 article-title: Omics-Driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis publication-title: Cell Metab doi: 10.1016/j.cmet.2020.06.016 – volume: 30 start-page: 367 year: 2020 ident: 2022060809381142300_bib1 article-title: COVID-19: towards understanding of pathogenesis publication-title: Cell Res doi: 10.1038/s41422-020-0327-4 – volume: 140 start-page: 110 year: 2002 ident: 2022060809381142300_bib12 article-title: Association between serum total and lipid-bound sialic acid concentration and the severity of coronary atherosclerosis publication-title: J Lab Clin Med doi: 10.1016/S0022-2143(02)00025-2 – volume: 61 start-page: 397 year: 1974 ident: 2022060809381142300_bib27 article-title: Characterization of temperature sensitive influenza virus mutants defective in neuraminidase publication-title: Virology doi: 10.1016/0042-6822(74)90276-1 – volume: 21 start-page: 122 year: 2017 ident: 2022060809381142300_bib22 article-title: Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind publication-title: Eur Rev Med Pharmacol Sci – volume: 20 start-page: 404 year: 2020 ident: 2022060809381142300_bib32 article-title: Correlation of serum N-Acetylneuraminic acid with the risk and prognosis of acute coronary syndrome: a prospective cohort study publication-title: BMC Cardiovasc Disord doi: 10.1186/s12872-020-01690-z – volume: 323 start-page: 1824 year: 2020 ident: 2022060809381142300_bib8 article-title: Pharmacologic treatments for Coronavirus disease 2019 (COVID-19): a review publication-title: JAMA – volume: 7 start-page: 15069 year: 2017 ident: 2022060809381142300_bib31 article-title: Sialidase inhibitors attenuate pulmonary fibrosis in a mouse model publication-title: Sci Rep doi: 10.1038/s41598-017-15198-8 – volume: 42 start-page: 1289 year: 2021 ident: 2022060809381142300_bib21 article-title: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation publication-title: Eur Heart J doi: 10.1093/eurheartj/ehaa575 – volume: 14 start-page: e008459 year: 2021 ident: 2022060809381142300_bib24 article-title: Prognostic value of elevated levels of plasma N-Acetylneuraminic acid in patients with heart failure publication-title: Circulation: Heart Failure – volume: 137 start-page: 1374 year: 2018 ident: 2022060809381142300_bib14 article-title: Functional metabolomics characterizes a key role for N-Acetylneuraminic acid in coronary artery diseases publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.117.031139 – volume: 10 start-page: 581 year: 2004 ident: 2022060809381142300_bib28 article-title: Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs publication-title: Emerg Infect. Dis. doi: 10.3201/eid1004.030458 – volume: 20 start-page: 363 year: 2020 ident: 2022060809381142300_bib2 article-title: The trinity of COVID-19: immunity, inflammation and intervention publication-title: Nat Rev Immunol doi: 10.1038/s41577-020-0311-8 – volume: 302 start-page: 143 year: 1991 ident: 2022060809381142300_bib13 article-title: Serum sialic acid concentration and cardiovascular mortality publication-title: BMJ doi: 10.1136/bmj.302.6769.143 – volume: 395 start-page: 497 year: 2020 ident: 2022060809381142300_bib20 article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China publication-title: Lancet North Am Ed doi: 10.1016/S0140-6736(20)30183-5 – volume: 384 start-page: 497 year: 2021 ident: 2022060809381142300_bib6 article-title: Repurposed antiviral drugs for COVID-19 - Interim WHO solidarity trial results publication-title: N Engl J Med doi: 10.1056/NEJMoa2023184 – volume: 191 start-page: 131 year: 2021 ident: 2022060809381142300_bib30 article-title: High-Fat diet—induced adipose tissue and liver inflammation and steatosis in mice are reduced by inhibiting sialidases publication-title: Am J Pathol doi: 10.1016/j.ajpath.2020.09.011 – volume: 324 start-page: 131 year: 2020 ident: 2022060809381142300_bib3 article-title: Monoclonal antibodies for prevention and treatment of COVID-19 publication-title: JAMA doi: 10.1001/jama.2020.10245 – volume: 120 start-page: c179 year: 2012 ident: 2022060809381142300_bib23 article-title: KDIGO clinical practice guidelines for acute kidney injury publication-title: Nephron Clin Pract doi: 10.1159/000339789 – volume: 45 start-page: 230 year: 2020 ident: 2022060809381142300_bib34 article-title: SARS-CoV-2: a potential novel etiology of fulminant myocarditis publication-title: Herz doi: 10.1007/s00059-020-04909-z – volume: 382 start-page: 1708 year: 2020 ident: 2022060809381142300_bib25 article-title: Clinical characteristics of coronavirus disease 2019 in China publication-title: N Engl J Med doi: 10.1056/NEJMoa2002032 – volume: 9 start-page: 1963 year: 2020 ident: 2022060809381142300_bib17 article-title: Coronaviruses: is sialic acid a gate to the eye of cytokine storm? From the entry to the effects publication-title: Cells doi: 10.3390/cells9091963 – volume: 384 start-page: 693 year: 2021 ident: 2022060809381142300_bib4 article-title: Dexamethasone in Hospitalized patients with COVID-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2021436 – volume: 18 start-page: 1094 year: 2020 ident: 2022060809381142300_bib5 article-title: Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy publication-title: J Thromb Haemost doi: 10.1111/jth.14817 – volume: 63 start-page: 1 year: 2020 ident: 2022060809381142300_bib7 article-title: Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19 publication-title: Sci China Life Sci – volume: 42 start-page: 3770 year: 2021 ident: 2022060809381142300_bib15 article-title: Neuraminidase 1 is a driver of experimental cardiac hypertrophy publication-title: Eur Heart J doi: 10.1093/eurheartj/ehab347 – volume: 12 start-page: 134 year: 2021 ident: 2022060809381142300_bib16 article-title: Host and viral determinants for efficient SARS-CoV-2 infection of the human lung publication-title: Nat Commun doi: 10.1038/s41467-020-20457-w – volume: 12 start-page: 670 year: 2015 ident: 2022060809381142300_bib36 article-title: Viral myocarditis—diagnosis, treatment options, and current controversies publication-title: Nat Rev Cardiol doi: 10.1038/nrcardio.2015.108 – volume: 33 start-page: 65 year: 2021 ident: 2022060809381142300_bib19 article-title: Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes publication-title: Cell Metab doi: 10.1016/j.cmet.2020.11.014 – volume: 842 start-page: 345 year: 2019 ident: 2022060809381142300_bib26 article-title: Sialidase activity in human pathologies publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2018.11.014 – volume: 395 start-page: 497 year: 2020 ident: 2022060809381142300_bib11 article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China publication-title: Lancet doi: 10.1016/S0140-6736(20)30183-5 – volume: 5 start-page: 287 year: 2020 ident: 2022060809381142300_bib35 article-title: Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-020-00360-y |
| SSID | ssj0001686283 |
| Score | 2.2459373 |
| Snippet | Abstract
Aims
The aim of this study was to investigate the effects of Neuraminidase inhibitors (NI) on COVID-19 in a retrospective study.
Methods and results... The aim of this study was to investigate the effects of Neuraminidase inhibitors (NI) on COVID-19 in a retrospective study. The study included an overall... Aims The aim of this study was to investigate the effects of Neuraminidase inhibitors (NI) on COVID-19 in a retrospective study. Methods and results The study... The aim of this study was to investigate the effects of Neuraminidase inhibitors (NI) on COVID-19 in a retrospective study. The study included an overall... The aim of this study was to investigate the effects of Neuraminidase inhibitors (NI) on COVID-19 in a retrospective study.AIMSThe aim of this study was to... |
| SourceID | pubmedcentral proquest gale pubmed crossref oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 392 |
| SubjectTerms | Analysis China Clinical outcomes Coronaviruses COVID-19 Hospital patients Infection Inhibitor drugs Liver Mortality Original Patient outcomes |
| Title | Neuraminidase inhibitor treatment is associated with decreased mortality in COVID-19 patients: a retrospective analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35294004 https://www.proquest.com/docview/2675281794 https://www.proquest.com/docview/2640044386 https://pubmed.ncbi.nlm.nih.gov/PMC8992306 |
| Volume | 8 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1LT-MwEB6xcNnLiscChYIMWsEFq3mn4YJ4CvYA1aqLeoscx1G7WtLSFBD_nhnHTRsk4JbIdhxlxuNvnJlvAH4hCHcyy29zK8wi7ikZcWK14lkkA0vYqW1JHW1xG1z_9X73_J45cCtMWOXUJmpDnQ4lnZG3HES2TpvU52T0yKlqFP1dNSU0vsGSjUiESjeEvXB2xkLpD5qJ07F8nwfojFW8jW5L9f_J51Fr9CykRTU_5vYlY51rKW9zyPN9AOXcjnS1DD8MlGSnpexXYEHlq3DQKbmoX49Yd5ZaVRyxA9aZsVS_rsEL0XIIYhZJcSNjg7w_SHB1j1kVes4GBRNGeipldGLLUo0yC7x90LgdMTwOZed39zcX3I6YoWktjplgYzUZD6eZnEwY9pOf0L267J5fc1OFgUtEdxP0VKOMUEjqhfg1E4mQSCBqidxAWn4iPanaCnEAXhBdmmO7ys68DGGWCjKBBmQdFvNhrjaBiSBUCgEbfu_E8xNixPUTxxWuG2Q4JmgAn4ogloahnApl_I_LP-VuXIosNiJrwGHVf1Ryc3zckyQa06LFJ0phcg_wvYj-Kj4NdfIZun4NaNZ64mKTteZ91IkvZ2tOVSY2FqGIZ_rbgL2qmR5PUW65Gj5RH7KontvGeTZKDaumQqBMNexxdFjTvaoD8YTXW_JBX_OFo0tNjubW56-1Dd8dSu3QochNWJyMn9QOAq5JsqtX1S4snV3edv7gXfeu9wYI9TAm |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6V9AAXxBtDgAVBuXQVvxMjVaj0oYSWEKEU9bZar9dKEDghTlvlx_HfmLHXTowEnHpLtOu15Zmd-WY98w3AawThbmoHPW5304j7WkWcWK14GqnQlk7i2KrIthiG_TP_43lwvgW_qloYSqusbGJhqJOZojPyjovI1u2R-ryf_-TUNYq-rlYtNKRprZDsFRRjprDjRK-uMITL9waHKO83rnt8ND7oc9NlgCtEL0uMxKKUvGzidxHdxwpdvkSvHHmhsoNY-Ur3NPo5_EF0YK7jaSf1U4QROkwlbhBc9gZs-3R-0oLtD0fD0Zf1IQ_VXxRUoK4dBDzEaLAmjvQ6evJNXc4780upbGo6suEYjXto1NxtQN8_Mzg3XOLxHbhtsCzbL5XvLmzp7B7sjEoy7NUuG69ru_JdtsNGa5rs1X24Il4QSdQmCXpSNs0m0xjNy4LVue9smjNp1EcnjI6MWVLA3Bz__igCBwwi8FJ28Pnr4JA7ETM8sfk7JtlCLxezqpSUSUO_8gDG1yGgh9DKZpl-DEyGXa0RMeL7jv0gJkreIHY96XlhiteEFvBKBEIZinTq1PFdlJ_qPVGKTBiRWfC2nj8vyUH-PpMkKshq4IpKmuIHfC7i3xL73aL6DWNPC9qNmbjbVWP4FerEf-_WrlRGGJOUi_UGsuBlPUzLU5pdpmcXNIdMuu_18D6PSg2rb4VIPaJRC7oN3asnEFF5cySbTgrCcozpKdJ98u_HegE3--NPp-J0MDx5CrdcqjMp8qLb0FouLvQzRH_L-LnZYwzENe_q31LkblI |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neuraminidase+inhibitor+treatment+is+associated+with+decreased+mortality+in+COVID-19+patients%3A+a+retrospective+analysis&rft.jtitle=European+heart+journal.+Cardiovascular+pharmacotherapy&rft.au=Wu%2C+Junfang&rft.au=Zhao%2C+Mingming&rft.au=Wei%2C+Haoran&rft.au=Li%2C+Chenze&rft.date=2022-07-01&rft.issn=2055-6837&rft.eissn=2055-6845&rft.volume=8&rft.issue=4&rft.spage=392&rft.epage=401&rft_id=info:doi/10.1093%2Fehjcvp%2Fpvac018&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_ehjcvp_pvac018 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2055-6837&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2055-6837&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2055-6837&client=summon |